Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs
Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of p...
Gespeichert in:
Veröffentlicht in: | Biomedicine & pharmacotherapy 2023-08, Vol.164, p.114934-114934, Article 114934 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 114934 |
---|---|
container_issue | |
container_start_page | 114934 |
container_title | Biomedicine & pharmacotherapy |
container_volume | 164 |
creator | Gioé-Gallo, Claudia Ortigueira, Sandra Brea, José Raïch, Iu Azuaje, Jhonny Paleo, M. Rita Majellaro, Maria Loza, María Isabel Salas, Cristian O. García-Mera, Xerardo Navarro, Gemma Sotelo, Eddy |
description | Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugs.
[Display omitted]
•Functional and binding data from the largest and most diverse collection of SCRAs published to date are presented.•We document 32 previously unexplored SCRAs that elicit the (R) configuration on the pendant amino acid chain.•New structural features defining SAR and SSR trends were identified.•Primary neuronal cells assessment evidenced an eventual neurotoxicity of tested SCRAs. |
doi_str_mv | 10.1016/j.biopha.2023.114934 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2820027126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332223007242</els_id><sourcerecordid>2820027126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-2b9cc9b1999ee9da6a96e068f2cb4a361c9c497e29a2ca138711717072be9f6c3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS1ERbeFb4CQj1yy-E_WiS9IqCpQqRI9lLM1mUyyXiX2YmeRylfol8ZVWo6cLI1_b57mPcbeS7GVQppPh23n43EPWyWU3kpZW12_Yhtpd6IyQjSv2UY0O11prdQ5u8j5IITYGd2-Yee6UdoI1WzY490e0gwYpzh6hIn7kP24XzKnmdLow8iHFGe-7IljQQEXSv4PLD4GHgcOfII0lr84TYQv0_wQimDxyBFCgM6H6HueCOm4xMRhjMHn4tFTMQuUeJ9OY37LzgaYMr17fi_Zz6_X91ffq9sf326uvtxWWIt2qVRnEW0nrbVEtgcD1pAw7aCwq0EbiRZr25CyoBCkbhspG9mIRnVkB4P6kn1c9x5T_HWivLjZZ6RpgkDxlJ1qlSjhSGUKWq8opphzosEdk58hPTgp3FMN7uDWGtxTDW6tocg-PDucupn6f6KX3AvweQWo3PnbU3IZPQWk3peUFtdH_3-HvyFdnj8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2820027126</pqid></control><display><type>article</type><title>Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Gioé-Gallo, Claudia ; Ortigueira, Sandra ; Brea, José ; Raïch, Iu ; Azuaje, Jhonny ; Paleo, M. Rita ; Majellaro, Maria ; Loza, María Isabel ; Salas, Cristian O. ; García-Mera, Xerardo ; Navarro, Gemma ; Sotelo, Eddy</creator><creatorcontrib>Gioé-Gallo, Claudia ; Ortigueira, Sandra ; Brea, José ; Raïch, Iu ; Azuaje, Jhonny ; Paleo, M. Rita ; Majellaro, Maria ; Loza, María Isabel ; Salas, Cristian O. ; García-Mera, Xerardo ; Navarro, Gemma ; Sotelo, Eddy</creatorcontrib><description>Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugs.
[Display omitted]
•Functional and binding data from the largest and most diverse collection of SCRAs published to date are presented.•We document 32 previously unexplored SCRAs that elicit the (R) configuration on the pendant amino acid chain.•New structural features defining SAR and SSR trends were identified.•Primary neuronal cells assessment evidenced an eventual neurotoxicity of tested SCRAs.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2023.114934</identifier><identifier>PMID: 37236027</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Abuse drugs ; Animals ; Cannabinoid Receptor Agonists - pharmacology ; Cannabinoids ; Cannabis ; CB1 ; CB2 ; Designer drugs ; Designer Drugs - toxicity ; Indazole ; Indole ; Ligands ; Mice ; SCRAs ; Structure-Activity Relationship ; Synthetic cannabinoid receptor agonists ; Synthetic cannabinoids NPS</subject><ispartof>Biomedicine & pharmacotherapy, 2023-08, Vol.164, p.114934-114934, Article 114934</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-2b9cc9b1999ee9da6a96e068f2cb4a361c9c497e29a2ca138711717072be9f6c3</citedby><cites>FETCH-LOGICAL-c408t-2b9cc9b1999ee9da6a96e068f2cb4a361c9c497e29a2ca138711717072be9f6c3</cites><orcidid>0000-0001-5218-6351 ; 0000-0001-9726-0455 ; 0000-0001-5571-2812 ; 0000-0002-5523-1979 ; 0000-0003-3490-7703</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2023.114934$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37236027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gioé-Gallo, Claudia</creatorcontrib><creatorcontrib>Ortigueira, Sandra</creatorcontrib><creatorcontrib>Brea, José</creatorcontrib><creatorcontrib>Raïch, Iu</creatorcontrib><creatorcontrib>Azuaje, Jhonny</creatorcontrib><creatorcontrib>Paleo, M. Rita</creatorcontrib><creatorcontrib>Majellaro, Maria</creatorcontrib><creatorcontrib>Loza, María Isabel</creatorcontrib><creatorcontrib>Salas, Cristian O.</creatorcontrib><creatorcontrib>García-Mera, Xerardo</creatorcontrib><creatorcontrib>Navarro, Gemma</creatorcontrib><creatorcontrib>Sotelo, Eddy</creatorcontrib><title>Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugs.
[Display omitted]
•Functional and binding data from the largest and most diverse collection of SCRAs published to date are presented.•We document 32 previously unexplored SCRAs that elicit the (R) configuration on the pendant amino acid chain.•New structural features defining SAR and SSR trends were identified.•Primary neuronal cells assessment evidenced an eventual neurotoxicity of tested SCRAs.</description><subject>Abuse drugs</subject><subject>Animals</subject><subject>Cannabinoid Receptor Agonists - pharmacology</subject><subject>Cannabinoids</subject><subject>Cannabis</subject><subject>CB1</subject><subject>CB2</subject><subject>Designer drugs</subject><subject>Designer Drugs - toxicity</subject><subject>Indazole</subject><subject>Indole</subject><subject>Ligands</subject><subject>Mice</subject><subject>SCRAs</subject><subject>Structure-Activity Relationship</subject><subject>Synthetic cannabinoid receptor agonists</subject><subject>Synthetic cannabinoids NPS</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS1ERbeFb4CQj1yy-E_WiS9IqCpQqRI9lLM1mUyyXiX2YmeRylfol8ZVWo6cLI1_b57mPcbeS7GVQppPh23n43EPWyWU3kpZW12_Yhtpd6IyQjSv2UY0O11prdQ5u8j5IITYGd2-Yee6UdoI1WzY490e0gwYpzh6hIn7kP24XzKnmdLow8iHFGe-7IljQQEXSv4PLD4GHgcOfII0lr84TYQv0_wQimDxyBFCgM6H6HueCOm4xMRhjMHn4tFTMQuUeJ9OY37LzgaYMr17fi_Zz6_X91ffq9sf326uvtxWWIt2qVRnEW0nrbVEtgcD1pAw7aCwq0EbiRZr25CyoBCkbhspG9mIRnVkB4P6kn1c9x5T_HWivLjZZ6RpgkDxlJ1qlSjhSGUKWq8opphzosEdk58hPTgp3FMN7uDWGtxTDW6tocg-PDucupn6f6KX3AvweQWo3PnbU3IZPQWk3peUFtdH_3-HvyFdnj8</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Gioé-Gallo, Claudia</creator><creator>Ortigueira, Sandra</creator><creator>Brea, José</creator><creator>Raïch, Iu</creator><creator>Azuaje, Jhonny</creator><creator>Paleo, M. Rita</creator><creator>Majellaro, Maria</creator><creator>Loza, María Isabel</creator><creator>Salas, Cristian O.</creator><creator>García-Mera, Xerardo</creator><creator>Navarro, Gemma</creator><creator>Sotelo, Eddy</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5218-6351</orcidid><orcidid>https://orcid.org/0000-0001-9726-0455</orcidid><orcidid>https://orcid.org/0000-0001-5571-2812</orcidid><orcidid>https://orcid.org/0000-0002-5523-1979</orcidid><orcidid>https://orcid.org/0000-0003-3490-7703</orcidid></search><sort><creationdate>202308</creationdate><title>Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs</title><author>Gioé-Gallo, Claudia ; Ortigueira, Sandra ; Brea, José ; Raïch, Iu ; Azuaje, Jhonny ; Paleo, M. Rita ; Majellaro, Maria ; Loza, María Isabel ; Salas, Cristian O. ; García-Mera, Xerardo ; Navarro, Gemma ; Sotelo, Eddy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-2b9cc9b1999ee9da6a96e068f2cb4a361c9c497e29a2ca138711717072be9f6c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abuse drugs</topic><topic>Animals</topic><topic>Cannabinoid Receptor Agonists - pharmacology</topic><topic>Cannabinoids</topic><topic>Cannabis</topic><topic>CB1</topic><topic>CB2</topic><topic>Designer drugs</topic><topic>Designer Drugs - toxicity</topic><topic>Indazole</topic><topic>Indole</topic><topic>Ligands</topic><topic>Mice</topic><topic>SCRAs</topic><topic>Structure-Activity Relationship</topic><topic>Synthetic cannabinoid receptor agonists</topic><topic>Synthetic cannabinoids NPS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gioé-Gallo, Claudia</creatorcontrib><creatorcontrib>Ortigueira, Sandra</creatorcontrib><creatorcontrib>Brea, José</creatorcontrib><creatorcontrib>Raïch, Iu</creatorcontrib><creatorcontrib>Azuaje, Jhonny</creatorcontrib><creatorcontrib>Paleo, M. Rita</creatorcontrib><creatorcontrib>Majellaro, Maria</creatorcontrib><creatorcontrib>Loza, María Isabel</creatorcontrib><creatorcontrib>Salas, Cristian O.</creatorcontrib><creatorcontrib>García-Mera, Xerardo</creatorcontrib><creatorcontrib>Navarro, Gemma</creatorcontrib><creatorcontrib>Sotelo, Eddy</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gioé-Gallo, Claudia</au><au>Ortigueira, Sandra</au><au>Brea, José</au><au>Raïch, Iu</au><au>Azuaje, Jhonny</au><au>Paleo, M. Rita</au><au>Majellaro, Maria</au><au>Loza, María Isabel</au><au>Salas, Cristian O.</au><au>García-Mera, Xerardo</au><au>Navarro, Gemma</au><au>Sotelo, Eddy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2023-08</date><risdate>2023</risdate><volume>164</volume><spage>114934</spage><epage>114934</epage><pages>114934-114934</pages><artnum>114934</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugs.
[Display omitted]
•Functional and binding data from the largest and most diverse collection of SCRAs published to date are presented.•We document 32 previously unexplored SCRAs that elicit the (R) configuration on the pendant amino acid chain.•New structural features defining SAR and SSR trends were identified.•Primary neuronal cells assessment evidenced an eventual neurotoxicity of tested SCRAs.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>37236027</pmid><doi>10.1016/j.biopha.2023.114934</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5218-6351</orcidid><orcidid>https://orcid.org/0000-0001-9726-0455</orcidid><orcidid>https://orcid.org/0000-0001-5571-2812</orcidid><orcidid>https://orcid.org/0000-0002-5523-1979</orcidid><orcidid>https://orcid.org/0000-0003-3490-7703</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0753-3322 |
ispartof | Biomedicine & pharmacotherapy, 2023-08, Vol.164, p.114934-114934, Article 114934 |
issn | 0753-3322 1950-6007 |
language | eng |
recordid | cdi_proquest_miscellaneous_2820027126 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Abuse drugs Animals Cannabinoid Receptor Agonists - pharmacology Cannabinoids Cannabis CB1 CB2 Designer drugs Designer Drugs - toxicity Indazole Indole Ligands Mice SCRAs Structure-Activity Relationship Synthetic cannabinoid receptor agonists Synthetic cannabinoids NPS |
title | Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T23%3A43%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20insights%20emerging%20from%20the%20characterization%20of%20a%20large%20collection%20of%20synthetic%20cannabinoid%20receptor%20agonists%20designer%20drugs&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Gio%C3%A9-Gallo,%20Claudia&rft.date=2023-08&rft.volume=164&rft.spage=114934&rft.epage=114934&rft.pages=114934-114934&rft.artnum=114934&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2023.114934&rft_dat=%3Cproquest_cross%3E2820027126%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2820027126&rft_id=info:pmid/37236027&rft_els_id=S0753332223007242&rfr_iscdi=true |